LogicBio Therapeutics Inc.
News
ContextLogic Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Simply Wall St ContextLogic ( NASDAQ:LOGC ) Second Quarter 2024 Results Key Financial Results Revenue: US$7.00m (down 91% from 2Q...\n more…
LOGC Stock Earnings: ContextLogic Misses EPS, Beats Revenue for Q2 2024
InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nLOGC stock results show that ContextLogic missed analyst estimates for earnings per share but beat on revenue for the second quarter of...\n more…
ContextLogic Inc. Reports Second-Quarter Financial Results
Globe Newswire OAKLAND, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- ContextLogic Inc. (Nasdaq: LOGC), ( ContextLogic, the Company, we or our ) today reported its financial results for the quarter and six...\n more…
Selling ContextLogic Shares at a Lower Price Than Current Market Value May Have Been a Costly Mistake for Insiders
Simply Wall St Despite the fact that ContextLogic Inc.'s (NASDAQ:LOGC) value has dropped 12% in the last week insiders who sold...\n more…
Rare Diseases Market is projected to grow at a CAGR of 12.27% by 2033: Visiongain
Globe Newswire As per the report by Visiongain, the Rare Diseases Market was valued at US$188.58 billion in 2022 and is projected to grow at a CAGR of 12.27% during the forecast period 2023-2033. Visiongain has published a new report entitledRare Diseases2023-2033. It includes profiles of Rare Diseases and ...\n more…
Rare Diseases Market is projected to grow at a CAGR of 12.27% by 2033: Visiongain Reports Ltd
Globe Newswire Visiongain has published a new report entitledRare Diseases2023-2033. It includes profiles of Rare Diseases and Forecasts Market Segment by Diseases (Cancer, Metabolic Diseases, Neurological Conditions, Hematologic Disorders, Infectious Diseases, Musculoskeletal Disorders, Cardiovascular Disorders, ...\n more…